Compare Neurocrine Biosciences Inc (NBIX) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Redwire Corporation — how do they compare? Neurocrine Biosciences Inc trades at $156.06 (market cap $16.46B), while Redwire Corporation trades at $13.45 (market cap $3.38B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.9× Redwire Corporation's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| NBIX | RDW | |
|---|---|---|
Market Cap | $16.46B | $3.38B |
Sector | Health | Technology |
52-Week High | $185.50 | $25.90 |
52-Week Low | $123.10 | $5.06 |
Enterprise Value | $16.48B | $2.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.
Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.
RDW trades at $13.49, up 2.82% with strong technical momentum as the stock approaches its consensus price target of $17.50. The company reported record Q2 2026 revenue of $117.1 million and a growing $542.1 million backlog, though it continues to post significant losses with a -57.26% net margin. Analyst sentiment remains overwhelmingly positive with 80% buy ratings, while technical indicators show bullish moving averages but overbought RSI conditions.
The outlook balances rapid revenue growth and strong defense contract momentum against persistent profitability challenges and cash burn. While the defense pivot and space technology positioning offer long-term potential, investors face dilution risk from ongoing financing needs and the company's path to profitability remains uncertain despite improving operational metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
